Physician profile
John C Bauer
NPI 1164474763
$12,044.27
in general payments reported to CMS, 2019-2025
44 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $500 · 2021: $1,985 · 2022: $2,818 · 2023: $1,968 · 2024: $1,919 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,472.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,473.06 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $958.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $691.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $546.99 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.30 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $425.53 | 2019-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $369.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $343.86 | 2019-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $254.78 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $254.31 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $249.96 | 2023-2025 | Gemtesa |
| Allergan, INC. | $224.95 | 2020 | |
| Amarin Pharma, INC. | $223.96 | 2019-2021 | |
| Pfizer INC. | $203.70 | 2019-2023 | |
| Eisai INC. | $199.39 | 2021-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.